IDEXX Laboratories' stock surged 5.31% in pre-market trading, as investors reacted positively to the company's release of its second fiscal quarter earnings report before the market open. The market is anticipating an adjusted earnings per share of $3.95 for the quarter.

In the previous quarter, IDEXX reported revenue of $1.141 billion, surpassing the consensus estimate of $1.109 billion, though adjusted EPS of $3.30 slightly missed the $3.40 estimate. Despite the EPS miss, the company raised its full-year guidance, citing improved clinical visit volumes and higher diagnostic frequency at veterinary practices. IDEXX has also recently expanded its Fecal Dx antigen testing platform with tapeworm detection capabilities and launched a Cancer Dx Panel for early detection of canine lymphoma in the UK, broadening its diagnostic coverage. Analyst consensus maintains an overweight rating with a mean price target of $713.46, well above current levels.